SCHEMBL19992500

SCHEMBL19992500

Cc1ccc(C2CCCN(C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.53
QDPR P09417 2/20 0.50
LSS P48449 2/20 0.46
APOBEC3A P31941 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
RAB9A P51151 3/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
ATM Q13315 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
SCN1A P35498 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
NPC1 O15118 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81500 0.92 QDPR (0.56) SLC18A3QDPRLSSRAB9AHTT
SCHEMBL23469162 0.85 SLC6A2 (0.55) LSSRAB9AHTTALDH1A1PROKR1
SCHEMBL12950820 0.85 SLC6A2 (0.55) LSSRAB9AHTTALDH1A1PROKR1
SCHEMBL23442954 0.84 LSS (0.65) SLC18A3QDPRLSSPROKR1
SCHEMBL13015008 0.84 QDPR (0.49) QDPRLSSAPOBEC3AAPOBEC3GATM
SCHEMBL9910976 0.83 DRD2 (0.56) SLC18A3SMN1; SMN2TSHR
SCHEMBL610439 0.82 QDPR (0.47) SLC18A3QDPRLSSAPOBEC3AAPOBEC3G
SCHEMBL14544198 0.81 RAB9A (0.50) SLC18A3QDPRLSSRAB9AHTT
SCHEMBL23443509 0.81 DRD2 (0.60) QDPRLSSALDH1A1SMN1; SMN2LMNA
SCHEMBL610312 0.80 QDPR (0.45) QDPRLSSAPOBEC3AAPOBEC3GALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020036386-A1 ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER 한국화학연구원 2020-02-20 WO disclosed
WO-2018053373-A1 USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS THE GENERAL HOSPITAL CORPORATION (US) 2018-03-22 WO disclosed